Expres2ion Biotechnologies

Expres2ion Biotechnologies

Expres2ion Biotechnologies is a Danish company focused on delivering custom human, parasite, and viral proteins for applications in vaccine and therapeutics development.

Expres2ion Biotechnologies is a Danish company focused on delivering custom human, parasite, and viral proteins for applications in vaccine and therapeutics development. The company was incorporated in 2010.

Technology

Expres2ion Biotechnologies's primary technology platform is called ExpreS2, a non-viral insect (drosophila) cell expression system that establishes stable polyclonal pools that provide high protein expression levels without selection pressure. The company says its system is designed for transient or stable transfections using vector DNA containing a very strong proprietary hybrid promoter.

ExpreS2 uses embryonic drosophila melanogaster (fruit fly) cells, called S2 cells. S2 cell lines were first created by Imogene Schneider in 1972.

The company cites a number of key features of its protein expression platform:

  • Expresses complex proteins including heterodimers and other multimers
  • Expressed proteins are very homogenous
  • Easy to access more protein from original producing pool
  • Consistent expression through cloning
  • Very high cell density without aggregation or toxic metabolite buildup issues
  • Flexible under various culture and process conditions
  • Suitable for perfusion processes using established equipment
  • Reduced risk of human contaminants, compared to other systems in use

Timeline

January 1, 2010
Expres2ion Biotechnologies was founded by Wian de Jongh.

Products

Product
Launch date
Industry
Website
Zika E80
15 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

ExpreS2ion announces EU grant award for the COVID-19 vaccine development programme

Web

March 6, 2020

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.